2,4-二甲氧基-5-三氟甲基苯胺 | 228401-47-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二甲氧基-5-三氟甲基苯胺
• 英文名称: 2,4-dimethoxy-5-(trifluoromethyl)aniline
• CAS: 228401-47-6
• 化学式: C₉H₁₀F₃NO₂
• mdl: MFCD00119625
• 分子量: 221.179
• InChiKey: RCOAFFRLRHZLJG-UHFFFAOYSA-N

物化性质

• 熔点：
  78-80

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  2,4-二甲氧基-5-三氟甲基苯胺 、 对甲苯异氰酸酯 在 乙醚 作用下， 以 乙酸乙酯 为溶剂， 反应 18.0h， 以to give the title compound as a white solid (0.36 g)的产率得到N-(2,4-dimethoxy-5-(trifluoromethyl)phenyl)-N'-(4-methylphenyl)urea
  参考文献：
  名称：

  INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

  摘要：

  本发明涉及使用一组芳基脲类化合物治疗细胞因子介导的疾病和蛋白酶酶介导的疾病，以及用于该疗法的制药组合物。

  公开号：

  US20090093526A1
• 作为产物：
  描述：

  1,5-dimethoxy-2-nitro-4-(trifluoromethyl)benzene 在 钯 氢气 作用下， 以 乙醇乙酸乙酯 为溶剂， 反应 1.0h， 以to afford 3.47 g (93% yield) of 2,4-dimethoxy-5-(trifluoromethyl)aniline as a light brown solid的产率得到2,4-二甲氧基-5-三氟甲基苯胺
  参考文献：
  名称：

  Positive allosteric modulators of the nicotinic acetylcholine receptor

  摘要：

  本发明提供了式I的化合物：这些化合物可以是药物盐或组合物的形式，可以是纯对映体形式或混合物，可用于制备药物，用于治疗已知涉及α7 nAChR的疾病或病症。

  公开号：

  US20050250816A1

文献信息

• Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
  申请人：Miller Scott

  公开号：US20080269265A1

  公开（公告）日：2008-10-30

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
  申请人：BAYER CORPORATION

  公开号：US20040102636A1

  公开（公告）日：2004-05-27

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗细胞因子介导的疾病和蛋白酶酶介导的疾病，以及用于该疗法的药物组合物。
• Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
  申请人：Bayer Corporation

  公开号：EP1449834A3

  公开（公告）日：2004-12-22

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• Inhibitors against the activation of ap-1 and nfat
  申请人：Muto Susumu

  公开号：US20060100257A1

  公开（公告）日：2006-05-11

  A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物，抑制AP-1的激活，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物中所选的一种，其中X代表连接基，其主链中的原子数为2至5（该连接基可以被取代），A代表氢原子或乙酰基，E代表芳基或取代的杂芳基，环Z代表芳烃，除了由式—O-A所表示的基团外，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义，或者是一个杂芳烃，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义。
• Medicament for treatment of diabetes
  申请人：Muto Susumu

  公开号：US20060111409A1

  公开（公告）日：2006-05-25

  A medicament for preventive and/or therapeutic treatment of diabetes or complications of diabetes which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O— A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种用于预防和/或治疗糖尿病或糖尿病并发症的药物，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物之一： 其中，X代表主链中原子数为2到5的连接基（该连接基可以被取代），A代表氢原子或乙酰基，E代表可以被取代的芳基或杂环芳基，环Z代表可以具有一个或多个取代基的芳基，除了由公式—O—A所表示的基团外，该芳基可以具有公式—X-E所表示的基团，其中每个X和E的含义与上述定义相同，或者可以具有一个或多个取代基的杂环芳基，除了由公式—O—A所表示的基团外，该杂环芳基可以具有公式—X-E所表示的基团，其中每个X和E的含义与上述定义相同。